heart failure – pharmaceutical daily

$Novartis’ Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes$

March 18, 2017 Off

Novartis’ Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

New analysis shows Novartis’ Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes. Novartis said on Saturday the new post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced ejection fraction (HFrEF) patients who also had diabetes.

October 31, 2016 Off

HeartWare recalls HVAD controller used in patients with heart condition

By Dino Mustafić

HeartWare is recalling the HVAD controller due to a loose power connector which may cause …

November 24, 2015 Off

Novartis’ heart failure tablet Entresto available in EU

By Dino Mustafić

European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.

September 25, 2015 Off

Novartis: New NIBR director named. Entresto closer to be available EU

By Dino Mustafić

Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…